Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Bristol Myers Squibb to cut 2,200 jobs as part of $1.5bn cost-savings drive
(Sharecast News) - US drugmaker Bristol Myers Squibb on Thursday announced plans to cut its workforce by 6% as part of a $1.5bn cost-savings programme, as it reported better-than-expected results for the first quarter. The company said it was launching a "Strategic Productivity Initiative" to deliver the cost savings, of which the majority will be reinvested to fund innovation and drive growth.
The initiative includes plans to lay off 2,200 employees this year (from its global headcount of 34,000), reduce management layers, "rationalise" its pipeline, consolidate sites and cut third-party spend.
The news came as BMS delivered net revenues of $11.9bn for the first three months of 2024, up from $11.3bn in 2023 and ahead of the $11.5bn consensus forecast.
However, losses per share widened significantly to $5.89 from a profit of $1.07 a share a year earlier, mainly as a result of a $12.1bn one-off non-tax-deductible charge for the acquisition of Karuna, which completed in March.
As a result of recent deals - which also included the completion of the RayzeBio acquisition February - BMS is now guiding to adjusted EPS of $0.40-0.70 this year, considerably down from the February guidance of $7.10-7.40.
The new guidance includes a $6.73-a-share negative impact from so-called acquired in-process research and development (or IPR&D) as a result of recent closed transactions.
"We had a good start to 2024, with revenue growth, important advances in our pipeline and the closure of several strategically important transactions," said Christopher Boerner, chair and chief executive officer.
"Our focus remains on strengthening the company's long-term growth profile. As a part of our continued evolution, we're executing a strategic productivity initiative that will allow us to be more agile, drive efficiency across the company, and prioritize investing in opportunities where we see the greatest potential to get the most promising medicines to patients as quickly as possible."
The stock was down 8% at $45.05 just before midday in New York.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.